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Abstract  
 
Background 
Minimal lipoprotein(a) [Lp(a)] target values are advocated for high-risk cardiovascular patients. We 
investigated the prognostic value of Lp(a) in the acute setting of patients with acute coronary 
syndromes (ACS).  
Methods 
Plasma levels of Lp(a) were collected at time of angiography from 1711 patients hospitalized for ACS 
in a multicenter Swiss prospective cohort. Associations between elevated Lp(a) ≥ 30 mg/dL (cut-off 
corresponding to the 75
th 
percentile of the assay) or Lp(a) tertiles at baseline, and major adverse 
cardiovascular events (MACE) at 1-year, defined as a composite of cardiac death, myocardial 
infarction or stroke were assessed using hazard ratios (HR) and 95% confidence intervals (CI) 
adjusting for traditional cardiovascular risk factors (age, sex, smoking, diabetes, hypertension, low-
density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C] and 
triglycerides.   
Results 
Lp(a) levels range between 2.5 mg/dL to 132 mg/dL with a median value of 6 mg/dL and a mean 
value of 14.2 mg/dL. A total of 276 patients (23.0%) had Lp(a) plasma levels ≥ 30 mg/dL). Patients 
with elevated Lp(a) were more likely to be of female gender, and to have higher levels of total 
cholesterol, LDL-C, HDL-C and triglycerides. Higher Lp(a) was associated with failure to reach the 
LDL-C target  < 1.8 mmol/l at 1-year (HR 1.71, 95% CI 1.13-2.58, P=0.01). No association was 
found between elevated Lp(a) and MACE at 1 year (HR 1.05, 95% CI 0.64-1.73), nor for Lp(a) 
tertiles (HR 0.82, 95% CI 0.52-1.28, P >0.20) or standardized continuous variables (0.98, 95% CI 
0.82-1.19 for each increase of standard deviation).  
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Conclusions 
Our real-world data suggest high Lp(a) levels at time of angiography are not predictive for 
cardiovascular outcomes in patients otherwise medically well controlled, but might be useful to 
identify patients who would not be on LDL-C targets one year after ACS.  
 
Introduction 
Lipoprotein(a) [Lp(a)] is a particle constituted of a low-density lipoprotein (LDL) with apolipoprotein 
B-100 (ApoB) bound to its surface and bound by a disulfide bridge to Apolipoprotein A (ApoA).
1
 
Although the physiological function of Lp(a) has not been elucidated, mechanistic studies have shown 
it to play a pathogenic role in the process of atherothrombosis.
2
 Epidemiological and Mendelian 
randomization studies provide support for a causal association between Lp(a) levels and 
cardiovascular disease (CVD).
3, 4
 It is estimated that 20% of the population has Lp(a) levels above 
50 mg/dL and that the risk for CVD is increased by 2- to 2.5-fold in individuals with levels above the 
90th percentile.
5
  However, the cut-off is assay dependant and some studies suggested a cut-off of 24 
mg/dL or 36 mg/dL in populational studies. 
6
 
The European Society of Cardiology (ESC) guidelines recommend measuring Lp(a) levels in selected 
patients at intermediate or high risk of CVD and associate values above the cut-off of 50 mg/dL with a 
very high cardiovascular (CV) risk.
7
 Patients presenting with acute coronary syndromes (ACS) are at 
high risk of recurrent CVD events and need intensive lipid-lowering therapies to lower LDL 
cholesterol (LDL-C) and improve their prognosis.
7
 This is especially true for patients with familial 
hypercholesterolemia (FH) who have a higher risk for recurrence of CVD events after an ACS. 
8
 In 
the secondary prevention setting, available data suggest a possible increase of CVD events with 
higher levels of Lp(a), but it remains unclear whether Lp(a) is a predictor independent of LDL-C or 
other prognostic factors.
9
 In addition, previous studies have not measured Lp(a) levels in the acute 
phase of ACS nor the prevalence of elevated Lp(a) levels in this specific high-risk setting. One of the 
main reasons has been the inability of traditional lipid-lowering agents, including statin and ezetimibe, 
to effectively lower Lp(a).
1
 Nevertheless, the more recent lipid-lowering monoclonal antibodies that 
inhibit proprotein convertase kexin/subtilisin 9 (PCSK9) have led to a 20–30% reduction in Lp(a) 
levels, as well as a lowering of the incidence of CVD events after ACS, suggesting that Lp(a) could 
represent an appealing biomarker of residual CV risk amenable to therapy. 
10
 
Despite these encouraging results, the clinical relevance of Lp(a) for clinical purposes has been 
questioned and its measurement is not widely applied in clinical practice. More data are needed in the 
ACS setting to clarify whether measuring Lp(a) could be helpful beyond the currently recommended 
This article is protected by copyright. All rights reserved.  
markers. Therefore, we evaluated the prevalence of elevated Lp(a) levels and investigated their 
prognostic value in a contemporary cohort of patients after ACS.  
 
Methods 
Study Population 
The Special Programme University Medicine Acute Coronary Syndromes and Inflammation (SPUM-
ACS) cohort consists of patients with a primary diagnosis of ACS referred for an angiography to one 
of four Swiss academic centers (Bern, Geneva, Lausanne, and Zürich, NCT01000701). 
11
  For the 
analysis of plasma Lp(a) measurements we extracted data from patients enrolled between December 
2009 and October 2012, as in our previous publications. 
11, 12
 Inclusion criteria comprised all females 
and males aged 18 years and older presenting within 5 days (preferably within 72 h) after pain onset 
associated with either one of the following primary diagnoses: ST-elevation myocardial infarction 
(STEMI), non-ST-elevation myocardial infarction (NSTEMI) or unstable angina. Patients had to 
present symptoms compatible with angina pectoris (chest pain and dyspnea) and fulfill at least one of 
the following criteria: (i) persistent ST-segment elevation or depression, T-inversion, or dynamic 
electrocardiogram (ECG) changes, new left bundle branch block (LBBB); (ii) evidence of positive 
troponin by local laboratory reference values (with a rise and/or fall in serial troponin levels); (iii) 
known coronary artery disease, specified as status after myocardial infarction, coronary artery bypass 
grafting (CABG), or percutaneous coronary intervention (PCI) or newly documented,  ≥50% stenosis 
of an epicardial coronary artery during initial catheterization. Exclusion criteria comprised severe 
physical disability, inability to comprehend the study or <1 year of life expectancy (for non-cardiac 
reasons). Follow-up was performed at 1 year (clinical visit) with events adjudicated by three 
independent experts using pre-specified adjudication forms. 
 
Familial hypercholesterolemia classification 
Based on a previous study, we used the validated Dutch Lipid Clinic Network algorithm for FH 
classification.
13
 In this algorithm, FH was considered possible when scoring 3–5 points, probable for 
6–8 points and definite for >8 points.
17
 The diagnosis of possible FH required both an elevated LDL 
cholesterol >4.9 mmol/L along with a family or personal history of premature atherosclerosis. Lipid-
lowering therapy included statin, fibrates, niacin, ezetimibe or resins. 
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Biomarker measurements 
Blood was drawn from the arterial sheath at coronary angiography (time-point 1, [T1]) and 
centrifuged at 2700 × g for 10 min at room temperature to obtain plasma, and then frozen and stored 
in aliquots at −80°C. Aliquots were measured blinded to patients' data by means of numbered codes 
and then merged with the clinical dataset. Plasma Lp(a) levels were determined by means of particle-
enhanced immunonephelometry (Siemens BN ProSpec
TM
 analyzer). The inter-assay coefficient of 
variation was <3.9%, the limit of detection (LoD) 2.5 mg/l and the limit of quantitation (LoQ) 100 
mg/l. For cases below the LoD, we imputed the minimal value as 2.5 mg/l (N= 509 patients). PCSK9 
levels were measured in each patient using ethylenediaminetetraacetic acid (EDTA) plasma by 
colorimetric enzyme-linked immunosorbent assay from R&D Systems (Minneapolis, MN, USA) 
according to the manufacturer's instructions. The minimal limit of detection was 0.625 ng/mL, the 
mean intra- and inter-assay coefficient of variation was at the accepted threshold of <8%. The cut-off 
of 30 mg/dL for this essay corresponds to the 75
th
 percentile in male Caucasian reference population. 
High-sensitive cardiac troponin T (hs-TnT), N-terminal-pro B-type natriuretic peptide (NT-proBNP) 
and high-sensitive C-reactive protein (hs-CRP) were measured in one serum aliquot per patient at the 
Zürich Core Laboratory using a electrochemiluminescence immunoassay on a cobas e 602
®
 reader (all 
Roche Diagnostics, Mannheim, Germany), with assay characteristics as reported by the 
manufacturer.
14
 
Study endpoints 
The primary endpoint was a composite of major adverse cardiovascular events (MACE) defined as 
cardiac death, myocardial infarction or stroke. The secondary clinical endpoints comprised all-cause 
death, cardiac death, myocardial infarction, cerebrovascular events (ischemic or hemorrhagic stroke 
including transient ischemic attack) and clinically indicated coronary revascularization. Clinical 
endpoints were adjudicated by a panel of independent experts (three certified cardiologists) blinded to 
the results of Lp(a). Participants were first followed up at 30 days by telephone by a trained study 
nurse and were then asked to attended a clinical visit at one-year post-ACS. If patients were unable to 
attend the clinic visit, follow-up was performed using either of the following alternatives, listed by 
order of preference: (i) phone call, (ii) postal mail or email, (iii) through family members, or (iv) via 
the primary care physician or cardiologist. 
Statistical methods 
The data were expressed as medians ± interquartile range for continuous variables and as numbers and 
percentages for categorical variables. The correlation between Lp(a) levels and other biomarkers was 
evaluated by a nonparametric test (Spearman rank correlation). Using logistic regression model 
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adjusted for previously tested confounding variables, 
15
 we evaluated the odds ratios (OR) and the 
95% confidence intervals (95% CI) of the association between Lp(a) values at time of the 
angiography and the achievement of LDL-C targets one year after ACS.  Continuous Lp(a) levels 
were categorized into tertiles to assess their association with clinical outcomes.
18
 We also classified 
patients into two groups, according to whether their Lp(a) levels were elevated (≥ 30 mg/dL) or 
normal (< 30 mg/dL). The time-to-first event or composite events were analyzed censoring patients at 
365 days, death, or last valid contact date. The univariable association of Lp(a) tertiles with all-cause 
death and secondary clinical outcomes was evaluated using Cox proportional hazards models and 
expressed with hazard ratios (HRs) and 95% confidence intervals (CI). We examined the 
proportionality of hazards using graphical methods and Schoenfeld residual tests. To increase 
statistical power, we additionally considered continuous Lp(a) concentrations, estimating the effect on 
clinical outcomes per 1 standard deviation (SD) increase. Effect estimates were presented as HR and 
95% CI. In the multivariable model, we adjusted for traditional CV risk factors (age, sex, smoking, 
diabetes, hypertension, LDL-C, high-density lipoprotein cholesterol [HDL-C], triglycerides and body 
mass index). All hypothesis tests were two-sided and the significance level wa set at 5%. Statistical 
analyses were performed using STATA software
®
 (Version 15, STATA Corp, College Station, TX, 
USA). Reporting of the study conforms to the STROBE statement along with references to the 
STROBE statement and the broader EQUATOR guidelines.
16 
 
Results 
Among the 2168 patients recruited, 1711 had available data on Lp(a) plasma levels at baseline (T1), 
Figure 1 depicts the distribution of Lp(a) levels, the range was between 2.5 mg/dL to 132 mg/dL with 
a median value of 6 mg/dL and a mean value of 14.2 mg/dL. A total of 92 patients (5.4%) had Lp(a) 
plasma levels ≥ 50 mg/dL and 276 patients (23.0%) has plasma level ≥ 30 mg/dL. Patients with 
elevated Lp(a) values were more likely to be female, and have higher levels of total cholesterol, LDL-
C and HDL-C PCSK9 (Table 1). Mean age was 63.9 ± 12.6 years, 15.2% had a history of MI, 31.3% 
were already on statin treatment and 2.3% on other lipid-lowering agents. The percentage of women 
significantly increased also across Lp(a) tertiles, passing from 17.0% in the lowest tertile to 25.2% in 
the highest tertile (P=0.003).  
Baseline Lp(a) values were significantly and positively correlated with total cholesterol, LDL-C and 
HDL-C values, and negatively with triglycerides at one-year follow-up (Table 2). No correlation was 
found between Lp(s) values and cardiac biomarkers (HsTnT, CK, NT-pro BNP) or inflammation (hs 
CRP). In addition, no significant differences in Lp(a) were observed according to the duration of chest 
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pain prior to blood draw. Discharge therapies were similar for both elevated and normal Lp(a) groups 
(Supplemental Table 1).  
At one-year follow-up, compliance to statin therapy was comparable between both groups (95% for 
patients with Lp(a) levels ≥ 30 mg/dL and 93% for Lp(a) levels < 30 mg/dL; P = 0.42, Supplemental 
Table 2), and the use of non-statin lipid-lowering agents was uncommon (5% vs. %, respectively; P = 
0.55). Regarding the subgroup of patients with available data for LDL-C at one year (Supplemental 
Table 2), patients with elevated Lp(a) had significantly higher mean LDL-C levels one-year after ACS 
compared to normal Lp(a) values (2.4±0.7 mmol/l vs. 2.2±0.9 mmol/l, P=0.003). Furthermore, a 
significantly lower proportion of patients with elevated Lp(a) values reached the LDL-C target of < 
1.8 mmol/l (24% vs. 38%, P=0.003). In the multivariate variables adjusting for potential confounding 
factors, high Lp(a) levels at time of ACS were associated with failure to reach LDL-C targets one year 
after ACS (Table 3, HR 1.71. 95% CI 1.13-2.58, P=0.011).  
The rate of MACE was similar between both Lp(a) groups, as were the clinical outcomes in crude and 
adjusted Cox regression models (Table 4). MACE rates were 8.3% for the group with elevated Lp(a) 
levels vs. 8.6% for patients with normal Lp(a) (HR 1.05, 95% CI 0.64–1.73, P =0.84). Equally, HRs 
for highest vs. lowest Lp(a) tertiles did not differ significantly for any of the clinical outcomes, 
whether taken separately or as a composite endpoint (Table 5, Figure 2) Results were also similar 
when considering Lp(a) as a continuous standardized value (HR 0.98, 95% CI 0.82-1.19 for each 
increase in SD). In sensitivity analyses, no significant interactions were found relative to the presence 
FH (Supplemental Table 3) and HRs were similar for nonfatal outcomes when using all-cause death 
as a competitive risk in the model (Supplemental Table 4).  
 
Discussion 
This large prospective cohort study of patients with ACS adds new evidence to the prognostic role of 
circulating Lp(a) plasma levels in patients with ACS: (i) the prevalence of elevated Lp(a) plasma 
levels at initial presentation is about 16% and an important amount of patients had values below the 
limit of quantification; (ii) higher Lp(a) plasma levels were associated with higher LDL-C values, but 
not with inflammation or cardiac injury markers; (iii) Lp(a) plasma levels obtained at initial 
presentation were not significantly associated with all-cause mortality, cardiac mortality, recurrent 
myocardial infarction or stroke at 1 year; (iv) patients with elevated Lp(a) plasma levels at initial 
presentation were less likely to reach the recommended target of LDL-C <1.8 mmol (<70 mg/dL) at 1 
year.  
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Our study is one of the largest to evaluate Lp(a) plasma levels specifically in ACS patients 
undergoing coronary angiography and, in most cases, primary percutaneous coronary intervention. 
Surprisingly, our findings indicate that assessing Lp(a) plasma levels in the acute ACS setting is likely 
to be devoid of clinical utility in terms of risk stratification. Compared to a primary prevention setting, 
the ACS population of the present cohort is characterized by very high use of statin, aspirin and 
P2Y12 inhibitors at discharge and at one year, which could potentially counteract the prothrombotic 
and proatherogenic properties of Lp(a). Furthermore, our data suggest that the acute condition of ACS 
might represent an pre-analytical factor able to substantially affect Lp(a) levels. However, we did not 
find any significant correlation between the levels of Lp(a) and the amount of inflammation or 
myocardial injury. Current evidence is controversial regarding the prognostic value of Lp(a) in 
secondary prevention and for patients on statin. In the Rosuvastatin Versus Atorvastatin (SATURN) 
trial, baseline and follow-up Lp(a) levels were not associated with changes in percent atheroma 
volume as measured with ultrasound.
17
 LDL-C decreased from 114 mg/dL to 60 mg/dL, while Lp(a) 
remained unchanged (17.4 mg/dL and 16.5 mg/dL, respectively) with statin therapy. The cut-off of 50 
mg/dl for Lp(a) was neither protective nor a risk factor for disease progression.
17
 In a sub-analysis of 
the Study of Dalcetrapib in Patients Hospitalized for an Acute Coronary Syndrome (dal-
OUTCOMES), no association was found between Lp(a) concentrations and major adverse outcomes 
including 4139 patients treated with statins: for a doubling of the dose of Lp(a), the level of risk for 
CVD was stagnant (HR 1.01, 95% CI 0.96-1.06, P=0.66).
18
 Similar results were also reported in 3 
different pooled studies with 6708 subjects known for coronary artery disease: the odds ratios (OR) 
were 1.03 (95% CI 0.96-1.11) for each increase in log-transformed standard deviation of Lp(a) or by 
quintile (highest vs. lowest OR 1.05, 95% CI 0.83-1.34).
9
 Some other data suggested that the risk 
associated with Lp(a) in patients with premature ACS was predominantly observed in those with 
concomitant elevated LDL-C levels, and not for patients with low LDL-C. 
19
 Recently, an individual 
patient-data meta-analysis of 29,069 patients from statin outcome trials suggested that baseline Lp(a) 
levels, as well as Lp(a) values on statin therapy were both associated with CVD events, especially for 
values higher than 50 mg/dL after adjustment for confounding factors.
20
 Therefore, the association 
between Lp(a) and major adverse cardiovascular events in a population already treated with statin, 
especially after ACS, is not consistent across literature.
9, 18
 Along these lines, the association of Lp(a) 
with LDL-C is, however, well established and Lp(a) is also considered as a marker for the diagnosis 
of FH.
1, 5
 Finally, we also observed that Lp(a) levels were higher in women, as recently reported in the 
FOURIER trial. 
21
 
Defining the Lp(a) cut-off for populations at risk is a source of controversy.
1
 The cut-off of 50 mg/dL 
was mainly based on the fact that 20% of subjects from the general population have Lp(a) levels 
above 50 mg/dL.
5
 Moreover, this threshold is assay-specific, as some studies have shown a significant 
risk increase already at Lp(a) levels above 30 mg/dL, as demonstrated for the assay used in this 
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study.
1
 No randomized controlled trial has shown a positive correlation between the reduction of 
Lp(a) and CVD events. Statin therapy has not shown to significantly impact Lp(a) levels.
1
 Niacin was 
also evaluated for reducing Lp(a) levels, but has since been withdrawn from the market following 
evidence of therapeutic futility.
22
 More recently, trials testing monoclonal antibodies directed against 
PCSK9 have reported a significant 25–30% decrease in Lp(a) values, as shown in a pooled analysis 
from 1359 patients.
10
  The reduction of Lp(a) was, however, significantly correlated with the 
percentage reduction of LDL-C and currently no evidence suggests that isolated reduction of Lp(a) 
could improve outcomes.
23
  Recently, treatment with antisense oligonucleotides targeting Apo(a) has 
shown that it can lower Lp(a) levels by up to 80% in individuals with elevated Lp(a). 
24
 A clinical 
study with CVD outcomes is now required to evaluate the specific impact of reducing Lp(a) alone. 
Along these lines, the sub-analysis of the Further Cardiovascular Outcomes Research with PCSK9 
Inhibition in Subjects with Elevated Risk (FOURIER) and the Evaluation of Cardiovascular 
Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY) data 
would clarify whether achieving Lp(a) target values <50 mg/dL in secondary prevention would 
improve prognosis or change the effect of PCSK9 inhibition on clinical outcomes.  
 
Strengths and limitations 
The major strength of this study is that it consists of a large cohort of patients with ACS with 
complete one-year follow-up data and characterized by the measurement of Lp(a) values at the time of 
angiography. The study population was medically well controlled, as illustrated by the extensive use 
of recommended treatments including statin and antiplatelet therapy, thereby offering a real-world 
setting for the assessment of biomarkers. However, we cannot exclude that our follow-up period of 
one year was not sufficient to detect a possible association at mid- or long-term. The recently 
published sub-analysis from the FOURIER study including 25,096 high-risk stable patients reported 
an association between Lp(a) and major adverse cardiovascular events with a median follow-up of 3 
years, and this independently of LDL-C.
21
 Although our data were observational and not randomized, 
we also took into consideration key confounding factors, such as inflammation and cardiac 
biomarkers, as well as the GRACE score. Other limitations include potential underpowered statistical 
analyses for the elevated Lp(a) strata (≥30 mg/dL), which is the reason why we did not use a more 
stringent cut-off of ≥ 50 mg/dL. However, analyses evaluating tertiles or standardized continuous 
Lp(a) corroborated our observations. Although we did not compare Lp(a) values measured at baseline 
with sample values collected during follow-up, our data do not suggest that Lp(a) levels were 
associated with the amount of inflammation or cardiac injury; rather, their distribution tends towards 
lower values than usually described in the high-risk population. Moreover, ACS causes a rapid 
decline in LDL-C levels, making their interpretation 24 h post-MI unreliable for the steady-state 
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level.
25
 Finally, as with all biomarker studies, pre-analytical (long-term stability of Lp(a) at −80°C is 
poorly known) as well as analytical aspects may have affected our findings. As samples were stored 
for 4-5 years prior to analysis, degradation of Lp(a) may have occurred.  
 
Conclusions 
Although Lp(a) is associated with proatherogenic and prothrombotic properties, the present study 
demonstrated that elevated Lp(a) values at time of angiography were not associated with worse 
clinical outcomes at one year in medically well controlled patients. However, measurement of Lp(a) 
might be useful to identify patients who would not be on LDL-C targets one year after ACS 
independently of other lipid particles. 
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Table 1. Baseline characteristics of 1711 patients with ACS 
   Lp(a) ≥ 30 mg/dL  Lp(a) < 30 mg/dL p value 
 (n=276) (n=1435)  
Demographics    
Age, yr. 64.1±11.7 63.8±12.7 0.75 
Woman, n (%) 36 (31.2) 284 (19.8) < 0.001    
BMI, kg/m
2
 26.6 ± 5.0 27.2 ± 4.3 0.03 
Hypertension, no. (%) 159 (57.6) 595 (41.5) 0.78 
Diabetes, no. (%) 44 (15.9) 279 (19.4) 0.17 
FH classification, no (%)   0.61 
   No FH 218 (80.8) 1146 (81.4)  
   Possible or probable 54 (19.9) 262 (18.6)  
Current Smoking, no. (%) 98 (35.8) 580 (41.3) 0.08 
Use of statin, no. (%) 97 (35.3) 435 (30.5) 0.12 
History of MI, no (%) 39 (14.1) 221 (15.4) 0.59 
History of malignancy, no (%) 27 (9.8) 106 (7.4) 0.17 
Family history CAD, no (%) 79 (29.2) 349 (24.8) 0.13 
Clinical presentation    
ACS
|
 type   0.91 
   STEMI, no (%) 142 (51.5) 722 (50.3)  
   NSTEMI, no (%) 124 (44.9) 655 (45.6)  
   Unstable angina 10 (3.6) 58 (4.0)  
Killip classification      0.08 
   I, no. (%) 226 (81.9) 1247 (86.9)  
II, no. (%) 36 (13.0) 128 (8.9)  
   III, no. (%) 8 (2.9) 24 (1.7)  
   IV, no. (%) 6 (2.2) 36 (2.5)  
SBP, mmHg 131.0 ± 23.7 129.8 ± 23.0 0.40 
DBP mmHg  75.0 ± 13.8 74.7 ± 14.9 0.72 
Revascularization (PCI or CABG) 255 (92.4) 1347 (93.9) 0.36 
Biochemical values    
Cholesterol (mmol/l) 5.1 ± 1.3 4.9 ± 1.3  0.01 
LDL-C (mmol/l)  3.7 ± 1.1 3.3 ± 1.1 < 0.001 
Triglycerides (mmol?l) 1.1 ± 0.8 1.4 ± 1.31 0.001 
HDL-C (mmol/l) 1.3 ± 0.2 1.2 ± 0.4 < 0.001 
PCSK9 (ng/ml)  341.3 ± 147.1 329.3 ± 145.9 0.22 
CRP (mg/L) 9.5 ± 1.6 11.1 ± 0.7 0.35 
Creatinine (mg/dl) 81.3 ± 27.1 84.3 ± 46.3 0.28 
Glucose (mmol/l) 6.9 ± 2.2 7.1 ± 2.8 0.48 
Data are expressed as mean ± standard deviation or number (no.) and percentages (%). Two-tailed Fisher's exact tests for 
dichotomous variables, larger Chi-squared test for +T-Test or Mann-Whitney-U tests for continuous variables, were 
utilized as appropriate. Abbreviations: ACS, acute coronary syndromes; BMI, body mass index; CABG, coronary artery 
bypass grafting; CAD, coronary artery disease; CRP, C-reactive protein; DBP, diastolic blood pressure; FH, familial 
hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, 
myocardial infarction;  NSTEMI, Non ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; 
PCSK9, proprotein convertase subtilisin kexin 9; PVD, peripheral vascular disease; SBP, systolic blood pressure; STEMI, 
ST-elevation myocardial infarction 
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Table 2 Correlations between Lp(a) and other biomarkers 
Biomarkers Rho # P-value 
   
LDL-C (mmol/l) 0.105 <0.001 
HDL-C (mmol/l) 0.116 <0.001 
Triglycerides (mmol/l)  -0.125 <0.001 
PCSK9 (ng/ml) 0.027 0.259 
Creatinine (mg/dl) -0.013 0.600 
hs-CRP (mg/l) -0.024 0.359 
Hs Troponin (μg/l)  -0.002 0.938 
CK (U/l) -0.004 0.889 
NT-pro BNP (ng/l)  0.020 0.429 
Glucose (mmol/l) -0.031 0.235 
# Spearman’s rank correlation rho for continuous variables; Rho=1 denotes perfect 
positive correlation, rho=-1 denotes perfect negative correlation and Rho=0 
absence of correlation. Abbreviations: CK, creatinine kinase; hs-CRP, high-
sensitive C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol; NT-pro BNP, N-terminal-pro B-type natriuretic 
peptide; PCSK9 proprotein convertase subtilisin kexin 9.   
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Table 3 Clinical Associated Factors With Failure to Achieve LDL-C Targets One 
Year After ACS 
 Odds Ratios (95% CI ) P-value 
Lp(a) Tertile   
1
st
 Tertile 1(Ref)  
2
nd
 Tertile 1.03 (0.70-1.53) 0.864 
3
rd
 Tertile 1.71 (1.13-2.58) 0.011 
Age (per year increase) 0.98 (0.97-1.00) 0.021 
Sex (women) 1.33 (0.84-2.11) 0.218 
Body mass index (per unit increase) 0.97 (0.93-1.01) 0.118 
History of diabetes  1.35 (0.87-2.09) 0.183 
Use of statin at one year 0.06 (0.01-0.3) <0.001 
LDL-C (per mmol/l increase) 2.21 (1.85-2.65) <0.001 
HDL-C (per mmol/l increase) 1.68 (1.00-2.85) 0.051 
Triglycerides (per mmol/l increase) 1.16 (1.03-1.31) 0.016 
Attendance to cardiac rehabilitation 0.68 (0.46-1.00) 0.047 
Abbreviations: ACS, acute coronary syndromes; CI, confidence intervals; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; Lp(a), Lipoprotein (a);  
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Table 4 Association between elevated Lp(a) values and clinical outcomes at one year 
Clinical outcomes 
at 365 days 
         
    Lp(a) ≥ 30 mg/dl 
      
      Lp(a) < 30 mg/dl 
HR (95% CI) 
 Number 
events/participants 
Number 
events/participants 
Unadjusted Adjusted for age, sex 
and CVRF¶ 
Composite MACE# 23/276 (8.3%) 123/1435 (8.6%) 0.97 (0.62-1.51) * 1.05 (0.64-1.73) * 
All-cause death 10/276 (3.6%) 75/1435 (5.2%) 0.69 (0.35-1.33) * 0.82 (0.39-1.73) * 
Cardiac death 9/276 (3.3%) 60/1435 (4.1%) 0.77 (0.38-1.55) * 0.95 (0.43-2.13) * 
MI 9/276 (3.3%) 50/1435 (3.5%) 0.93 (0.46-1.88) * 1.02 (0.47-2.19) * 
Stroke 5/276 (1.8%) 21/1435 (1.5%) 1.23 (0.46-3.26) * 1.05 (0.35-3.16) * 
Revascularization 16/276 (5.8%) 81/1435 (5.6%) 1.00 (0.59-1.72) * 1.07 (0.62-1.87) * 
# MACE was defined as a composite of cardiac death, MI and stroke events. 
¶ CVRF was defined as smoking, history of hypertension, history of diabetes, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, 
triglycerides and body mass index.  * P-value > 0.20.  Abbreviations: CI, confidence intervals; CVRF, cardiovascular risk factor; HR, hazard ratio; 
Lp(a), Lipoprotein(a); MACE, major adverse cardiovascular events.  
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Table 5 Association between Lp(a) tertiles and clinical outcomes at one year 
 1
st 
Tertile 
(<2.5-3.1 mg/dL) 
2
nd
 Tertile 
(3.1-12.4 mg/dL) 
3
rd 
Tertile 
(12.5-132 mg/dL) 
Per SD increase 
Composite MACE§     
Number events/participants 56/571 (9.8%) 49/572 (8.6%) 41/568 (7.2%)  
Crude HR and 95% CI 1 (Ref) 0.87 (0.59-1.27) 0.73 (0.49-1.09) *** 0.94 (0.79-1.12) 
Adjusted HR and 95% CI 1 (Ref) 0.89 (0.59-1.35) 0.82 (0.52-1.28) 0.98 (0.82-1.19) 
All-cause death     
Number events/participants 36/571 (6.3%) 31/572 (5.4%) 18/568 (3.2%)  
Crude HR and 95% CI 1 (Ref) 0.85 (0.53-1.38) 0.49 (0.28-0.87)  0.75 (0.56-0.99) * 
Adjusted # HR and 95% CI 1 (Ref) 0.88 (0.52-1.50) 0.62 (0.33-1.16) *** 0.82 (0.60-1.12)  
Cardiac death 
Number events/participants 31/571 (5.4%) 23/572 (4.0%) 15/568 (2.6%)  
Crude HR and 95% CI 1 (Ref) 0.74 (0.43-1.26) 0.48 (0.26-0.89) * 0.75 (0.55-1.02) ** 
Adjusted HR and 95% CI 1 (Ref) 0.79 (0.43-1.43) 0.66 (0.33-1.31)  0.86 (0.61-1.20) 
Myocardial Infarction 
Number events/participants 22/571 (3.9%) 21/572 (3.7%) 16/568 (2.8%)  
Crude HR and 95% CI 1 (Ref) 0.95 (0.52-1.72) 0.72 (0.38-1.37) 0.89 (0.67-1.19) 
Adjusted HR and 95% CI 1 (Ref) 0.91 (0.48-1.71) 0.75 (0.38-1.50) 0.91 (0.67-1.24) 
Stroke     
Number events/participants 8/571 (1.4%) 6/572 (1.1%) 12/568 (2.1%)  
Crude HR and 95% CI 1 (Ref) 0.74 (0.26-2.14) 1.50 (0.61-3.66) 1.31 (0.99-1.74) ** 
Adjusted HR and 95% CI 1 (Ref) 0.60 (0.19-1.88) 1.09 (0.40-2.95) 1.24 (0.91-1.68) *** 
Revascularization     
Number events/participants 38/571 (6.7%) 33/572 (5.8%) 26/568 (4.6%)  
Crude HR and 95% CI 1 (Ref) 0.86 (0.54-1.37) 0.66 (0.40-1.09) *** 0.92 (0.75-1.14) 
Adjusted HR and 95% CI 1 (Ref) 0.87 (0.53-1.43) 0.71 (0.42-1.20) *** 0.95 (0.76-1.18) 
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# Adjusted model included age, sex, smoking, history of hypertension, history of diabetes, low-density lipoprotein-cholesterol, high-density lipoprotein 
triglycerides and body mass index.  * p value < 0.05, ** p value 0.05-0.10. *** p value 0.10–0.20. § MACE was defined as a composite of cardiac death, 
MI and stroke events. Abbreviations; CI, confidence intervals; HR, hazard ratio; SD, standard deviation 
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FIGURES 
 
 
 
Figure 1 Distribution of Lipoprotein(a) Levels At Time of Angiography in Patients With 
Acute Coronary Syndrome.  
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Figure 2 Kaplan-Meier curve for major adverse cardiac events according to Lp(a) 
tertiles.  
Abbreviations: Lp(a), lipoprotein(a); MACE, major adverse cardiovascular events 
 
 
 
 
 
